| What line of work are you in? https://www.expertbrand.com/azithromycin-pharmacy2us-00b1.pdf azithromycin pharmacy2us
The widely praised deals will give Cubist, one of the few big players in U.S. antibiotics in the United States, an additional $600 million to $1 billion in revenue on an annual basis from the companies' lead drugs. Antibiotics has often been shunned by many big pharma firms as a field of research due to poor returns.
|